是沙利度胺的副作用吗？
请回想一下，我们为什么要禁止使用沙利度胺。
结论：沙利度胺治疗难治性多发性骨髓瘤有效。
Conclusion: Thalidomide is effective in the treatment of refractory multiple myeloma.
目的：评价沙利度胺在血液病中的研究进展及应用概况。
OBJECTIVE: to evaluate research progress and the usage of thalidomide in hematologic disease.
目的探讨沙利度胺对血液肿瘤患者内皮细胞功能的影响。
Objective to assess the influences of thalidomide on function of endothelial cells in patients with hematologic tumors.
近年来沙利度胺被应用于MM的治疗中，并取得了巨大成功。
Recent years thalidomide (Thd) has been applied for MM and succeeds in treating MM.
介绍了沙利度胺在皮肤病治疗中的应用和作用机制等方面的进展。
This article summarizes the application and mechanism of action of thalidomide in the treatment of some skin diseases.
临床研究证实，难治性克罗恩病的患者对沙利度胺的治疗有所反应。
Clinical studies have confirmed that refractory Crohn disease patients respond to thalidomide.
目的：观察沙利度胺对大鼠实验性肝纤维化的治疗效果并探讨其作用机制。
AIM: To investigate the therapeutic effects and mechanism of thalidomide on hepatic fibrosis in rats.
目的：观察沙利度胺联合化疗治疗多发性骨髓瘤(MM)的疗效和安全性。
Objective: To observe the curative effect and safety of thalidomide in treating multiple myeloma (MM).
沙利度胺组临床症状改善较快，退黄时间和转氨酶下降速度与对照组相近。
Meanwhile the clinical symptoms in thalidomide group improved faster, and the improvement of liver function was comparable with control group.
此外也有证据表明怀孕期服用处方药如沙利度胺和丙戊酸会使婴儿面临较高的罹患asd的风险。
And there's some evidence linking the use of prescription drugs — such as thalidomide and valproic acid — during pregnancy with a higher risk of ASDs.
沙利度胺作为一种镇静剂于1956年上市，但是由于其致畸的副作用而很快被禁用。
Thalidomide was first introduced to the market in 1956 as a sedative, but was abandoned soon because it was correlated with severe birth defects.
方法：选取25例初治或复治MM病人，采用沙利度胺联合VAD、VTD等方案治疗。
Methods:25 newly diagnosed or relapsed MM cases were treated with T-VAD or T-VTD.
目的：探讨卡培他滨联合沙利度胺治疗晚期结直肠癌的近期疗效及癌组织胸苷磷酸化酶的表达。
Objective: To study the efficacy of combined capecitabine with thalidomide in treatment of advanced colorectal cancer and expression of thymidine phosphorylase in colorectal cancer tissue.
一些有前景的药物如沙利度胺、蛋白酶体抑制剂、砷剂等的应用使MM的治疗得到了极大的突破。
Applications of several perspective drugs such as Thalidomide, proteasomes inhibitor, arsenical and other agents bring galactic breakthrough to the treatments of MM.
本发明公开了沙利度胺及其药学可接受的前药、盐、溶剂化物、水合物或包合物的药物组合物和单一单位剂型。
Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed.
本发明公开了沙利度胺及其药学可接受的前药、盐、溶剂化物、水合物或包合物的药物组合物和单一单位剂型。
Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed.
应用推荐